Trials / Completed
CompletedNCT04742660
The Effect of Glycyrrhizin on the Occurrence of Postoperative Nausea and Vomiting
The Effect of Administration of Glycyrrhizin During Induction Period on the Occurrence of Postoperative Nausea and Vomiting After Breast Surgery
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 224 (actual)
- Sponsor
- Konkuk University Medical Center · Academic / Other
- Sex
- Female
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The investigators investigate the association between the administration of glycyrrhizin during induction of general anesthesia and the occurrence of postoperative nausea and vomiting (PONV) in patients undergo breast surgery
Detailed description
Postoperative nausea and vomiting (PONV) is one of a common complication after general anesthesia with 30-50% of incidence, increased up to 80% in high risk group. The risk factors of PONV include women population, the previous history of PONV, motion sickness in usual life, non-smoker, exposure to inhalants, perioperative opioid and laparoscopic surgery. Women population is a strong risk factor of PONV. Although perioperative management of PONV based on a guideline has been done in a lot of medical centers worldwide, the incidence of PONV is still reported relatively high. The main ingredient of Glycyrrhizin is liquorice which has been used as antispasmodics, antiemetics or treatment for gastric ulcer in oriental medicine. Utilizing these effects of liquorice, the investigators investigate whether the addition of glycyrrhzin to conventional antiemetics is effective to decrease the incidence of PONV and improvement of severity of PONV.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ammonium Glycyrrhizinate | In control group, we assess the incidence and severity of PONV when participants are aministered ramosetron and placebo. In intervention group, the outcomes are assessed as a result of administration of ramosetron and glycyrrhizin. |
Timeline
- Start date
- 2021-05-11
- Primary completion
- 2022-03-08
- Completion
- 2022-03-10
- First posted
- 2021-02-08
- Last updated
- 2024-10-18
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04742660. Inclusion in this directory is not an endorsement.